Roman Fabbricatore

A trial for BNT326/YL202 in EGFR-mutated NSCLC or HR-positive HER2-negative breast cancer has paused enrollment due to a large illness or injury risk.

Data from the phase 3 PALOMA study showed subcutaneous amivantamab had comparable ORR to intravenous administration for patients with EGFR-mutated NSCLC.

UGN-102 also demonstrated a 79.6% complete response rate at 3 months in the phase 3 ENVISION trial.

Patients with hormone receptor-positive breast cancer experienced weight loss when given a plant-based diet plus exercise.

Phase 2a data show no dose-limiting toxicities with SLS009 among patients with relapsed/refractory acute myeloid leukemia.